Guided Therapeutics (GTHP) Long-Term Debt Repayments (2018 - 2025)

Guided Therapeutics has disclosed Long-Term Debt Repayments across 8 years of filings, most recently posting $187000.0 for Q4 2025.

• Long-Term Debt Repayments for Q4 2025 came in at $187000.0, down 6.03% year-over-year; the trailing twelve-month figure through Dec 2025 was $499000.0 (up 13.93% YoY), and the FY2025 annual result was $499000.0, up 13.93% from the prior year.
• Long-Term Debt Repayments came in at $187000.0 for Q4 2025 at Guided Therapeutics, up from $94000.0 in the prior quarter.
• In the past five years, Long-Term Debt Repayments ranged from a high of $811000.0 in Q2 2021 to a low of $41000.0 in Q2 2023.
• The 5-year median for Long-Term Debt Repayments is $116500.0 (2024), against an average of $180944.4.
• Across the five-year window, Long-Term Debt Repayments plunged 94.7% in 2022 and surged 342.22% in 2024, its largest moves.
• Guided Therapeutics' Long-Term Debt Repayments stood at $811000.0 in 2021, then plunged by 90.75% to $75000.0 in 2022, then sank by 40.0% to $45000.0 in 2023, then soared by 342.22% to $199000.0 in 2024, then dropped by 6.03% to $187000.0 in 2025.
• The last three Long-Term Debt Repayments figures came in at $187000.0 (Q4 2025), $94000.0 (Q3 2025), and $71000.0 (Q2 2025), per Business Quant data.